SEGMENTED INFORMATION (Tables)

3 Months Ended

Mar. 31, 2023

SEGMENTED INFORMATION

Schedule of Segmented Revenue and Net Profit/(Loss)

	BioNexus Malaysia			Chemrex			BGLC			Total
	Three months ended March 31, 2023
REVENUE	$	7,436		$	2,369,769		$	-		$	2,377,205
COST OF REVENUE		(5,347	)		(2,002,961	)		-			(2,008,308	)
GROSS /PROFIT		2,089			366,808			-			368,897
OTHER INCOME		1,126			116,218			-			117,344
OPERATING EXPENSES
General and administrative		(46,255	)		(383,177	)		(107,440	)		(536,872	)
(LOSS)/PROFIT FROM OPERATIONS		(43,040	)		99,849			(107,440	)		(50,631	)
FINANCE COSTS		(666	)		(1,779	)		-			(2,445	)
(LOSS)/PROFIT BEFORE TAX		(43,706	)		98,070			(107,440	)		(53,076	)
Tax expense		-			(15,990	)		-			(15,990	)
NET (LOSS)/PROFIT	$	(43,706	)	$	82,080		$	(107,440	)	$	(69,066	)

	BioNexus Malaysia			Chemrex			BGLC			Total
	Three months ended March 31, 2022
REVENUE	$	24,269		$	3,004,676		$	-		$	3,028,945
COST OF REVENUE		(8,038	)		(2,664,574	)		-			(2,672,612	)
GROSS PROFIT		16,231			340,102			-			356,333
OTHER INCOME		2,076			44,306			12			46,394
OPERATING EXPENSES
General and administrative		(44,042	)		(297,769	)		(26,225	)		(368,036	)
(LOSS)/PROFIT FROM OPERATIONS		(25,735	)		86,639			(26,213	)		34,691
FINANCE COSTS		(799	)		(2,527	)		-			(3,326	)
PROFIT/(LOSS) BEFORE TAX		(52,269	)		170,751			(52,426	)		31,365
Tax expense		-			(14,299	)		-			(14,299	)
NET PROFIT/(LOSS)	$	(52,269	)	$	502,730		$	(52,426	)	$	17,066

	As of March 31, 2023 and December 31, 2022
	Total Assets				Total Liabilities
	2023		2022		2023		2022
BGLC & Bionexus	$	509,574	$	677,477	$	93,034	$	108,390
Chemrex		7,677,067		8,062,685		1,536,699		1,966,759
TOTAL		8,186,641		8,740,162		1,629,733		2,075,149